Details of the Active Pharmaceutical Ingredient (API)

General Information of API (ID: D01090)
Name
Fluocinonide
Synonyms    Click to Show/Hide the Synonyms of This API
fluocinonide; 356-12-7; Fluocinolide; Lidex; Vanos; Fluocinolide acetate; Fluocinolone acetonide acetate; Fluonex; LIDEX-E; Lonide; Lyderm; Fluocinonidum [INN-Latin]; Fluocinonide Emulsified Base; Fluocinonido [INN-Spanish]; Fluocinolone acetonide 21-acetate; Lidex E; C26H32F2O7; UNII-2W4A77YPAN; Fluocinonide, micronised; 2W4A77YPAN; MLS000028476; Fluocinonido; Fluocinonidum; SMR000058331; DSSTox_CID_25307; DSSTox_RID_80793; DSSTox_GSID_45307; Fluocinonide [USAN:BAN:INN:JAN]; (6ALPHA,11BETA,16ALPHA)-21-(ACETYLOXY)-6,9-DIFLUORO-11-HYDROXY-16,17-[(1-METHYLETHYLIDENE)BIS(OXY)]-PREGNA-1,4-DIENE-3,20-DIONE; 2-((2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-6a,8a,10,10-tetramethyl-4-oxo-2,4,6a,6b,7,8,8a,8b,11a,12,12a,12b-dodecahydro-1H-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl acetate; Fluocinonide(Vanos); Vanos (TN); EINECS 206-597-6; LIDEX (TN); NSC 101791; NCGC00016436-01; CAS-356-12-7; Prestwick_1066; Fluocinonide (Vanos); Fluocinonide(Vanos)/; 6alpha,9-Difluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione, cyclic 16,17-acetal with acetone, 21-acetate; Pregna-1,4-diene-3,20-dione, 21-(acetyloxy)-6,9-difluoro-11-hydroxy-16,17-((1-methylethylidene)bis(oxy))-, (6alpha,11beta,16alpha)-; Fluocinonide [USAN:USP:INN:BAN:JAN]; Opera_ID_1780; Prestwick0_000774; Prestwick1_000774; Prestwick2_000774; Prestwick3_000774; FLUOCINOMIDE ACETATE; SCHEMBL4262; CHEMBL1501; BSPBio_000848; Pregna-1,4-diene-3,20-dione, 6-alpha, 9-difluoro-11-beta,16-alpha,17,21-tetrahydroxy-, cyclic17-acetal with acetone, 21-acetate; SPBio_002787; BPBio1_000934; CHEBI:5109; GTPL7078; DTXSID8045307; Fluocinonide (JP17/USP/INN); Fluocinonide, >=98% (HPLC); HMS1570K10; HMS2097K10; HMS2234H04; HMS3259N05; HMS3714K10; HY-B0485; ZINC3977978; Tox21_110438; ABP000638; MFCD00079302; s2608; AKOS015896516; Tox21_110438_1; AC-2071; BCP9000697; CCG-220774; DB01047; NC00621; YF10077; FLUOCINONIDE ACETONIDE 21-ACETATE; NCGC00022398-03; NCGC00022398-05; BS-17093; Pregna-1,4-diene-3,20-dione, 6alpha,9-difluoro-11beta,16alpha,17,21-tetrahydroxy-, cyclic 16,17-acetal with acetone, 21-acetate (8CI); C07007; D00325; 20527-EP2371811A2; 356F127; SR-01000003097; Q5462791; SR-01000003097-3; W-106660; BRD-K57886322-001-03-4; BRD-K57886322-001-12-5; Fluocinonide, United States Pharmacopeia (USP) Reference Standard; [2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-8-yl]-2-oxoethyl] acetate; 1,4-PREGNADIEN-6ALPHA,9ALPHA-DIFLUORO-11BETA,16ALPHA,17,21-TETROL-3,20-DIONE 16,17-ACETONIDE 21-ACETATE; 2-((2S,6aS,6bR,7S,8aS,8bS,11aR,12aS,12bS)-2,6b-difluoro-7-hydroxy-6a,8a,10,10-tetramethyl-4-oxo-1,2,4,6a,6b,7,8,8a,11a,12,12a,12b-dodecahydro-8bH-naphtho[2',1':4,5]indeno[1,2-d][1,3]dioxol-8b-yl)-2-oxoethyl acetate; 2-[(1S,2S,4R,8S,9S,11S,12R,13S,19S)-12,19-difluoro-11-hydroxy-6,6,9,13-tetramethyl-16-oxo-5,7-dioxapentacyclo[10.8.0.0^{2,9}.0^{4,8}.0^{13,18}]icosa-14,17-dien-8-yl]-2-oxoethyl acetate
Clinical Status
Approved
PubChem CID
9642
Formula
C26H32F2O7
Canonical SMILES
CC(=O)OCC(=O)[C@@]12[C@@H](C[C@@H]3[C@@]1(C[C@@H]([C@]4([C@H]3C[C@@H](C5=CC(=O)C=C[C@@]54C)F)F)O)C)OC(O2)(C)C
InChI
1S/C26H32F2O7/c1-13(29)33-12-20(32)26-21(34-22(2,3)35-26)10-15-16-9-18(27)17-8-14(30)6-7-23(17,4)25(16,28)19(31)11-24(15,26)5/h6-8,15-16,18-19,21,31H,9-12H2,1-5H3/t15-,16-,18-,19-,21+,23-,24-,25-,26+/m0/s1
InChIKey
WJOHZNCJWYWUJD-IUGZLZTKSA-N
   Click to Show/Hide the Molecular Data (Structure/Property) of This API
Structure
<iframe style="width: 300px; height: 300px;" frameborder="0" src="https://embed.molview.org/v1/?mode=balls&cid=9642"></iframe>
3D MOL 2D MOL
Physicochemical Properties Molecular Weight 494.5 Topological Polar Surface Area 99.1
XlogP 3.2 Complexity 1070
Heavy Atom Count 35 Rotatable Bond Count 4
Hydrogen Bond Donor Count 1 Hydrogen Bond Acceptor Count 9
Full List of Drug Formulations (DFMs) Containing This API
          Fluocinonide 0.1% cream Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Carbomer Homopolymer Type C (Allyl Pentaerythritol Crosslinked); Citric Acid Monohydrate; Diisopropanolamine; Glycerin; Glyceryl Monostearate; Glyceryl 1-Stearate; Isostearic Acid; Peg-100 Stearate; Propylene Glycol; Water
                   Dosage Form Cream
                   Company Perrigo New York
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Isostearic acid DIG Info Olfactory receptor 51E2 (EC50 = 9.8 nM) [1]
Diisopropanolamine DIG Info Leukemia L1210 cells (IC50 = 600 nM) [2]
Glyceryl monostearate DIG Info Prostate cancer LNCaP cells (IC50 > 100000 nM) [3]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
          Fluocinonide 0.05% solution Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Alcohol; Diisopropyl Adipate; Anhydrous Citric Acid; Propylene Glycol; Water
                   Dosage Form Solution
                   Company Glasshouse Pharmaceuticals Limited Canada
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Kyselina citronova DIG Info Perilipin-1 (IC50 = 3708 nM) [5]
Diisopropyl adipate DIG Info Cholesterol 25-hydroxylase (IC50 = 110000 nM) [6]
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
          Fluocinonide 0.05% cream Click to Show/Hide the Full List of Formulation(s):          1 Formulation(s)
             Drug Formulation 1 DFM Info click to show the detail info of this DFM
                   All DIGs    Click to Show/Hide the Full List of DIGs in This DFM
Stearyl Alcohol; Polyethylene Glycol 8000; Propylene Glycol; 1, 2, 6-Hexanetriol; Citric Acid Monohydrate
                   Dosage Form Cream
                   Company A-S Medication Solutions
                   DIG(s) with
                   Biological Activity
DIG Name DIG Info Representative Biological Activity of This DIG REF
Propylene glycol DIG Info Albendazole monooxygenase (Inhibition ratio < 20 %) [4]
References
1 US patent application no. 20180116992A1, Modulators of Prostate-Specific G-Protein Receptor (PSGR/OR51E2) and Methods of Using Same.
2 Synthesis and evaluation of hydroxylated polyamine analogues as antiproliferatives. J Med Chem. 2001 Jul 19; 44(15):2451-9.
3 Lignanamides and nonalkaloidal components of Hyoscyamus niger seeds. J Nat Prod. 2002 Feb; 65(2):206-9.
4 Pharmaceutical excipients inhibit cytochrome P450 activity in cell free systems and after systemic administration. Eur J Pharm Biopharm. 2008 Sep;70(1):279-88.
5 PubChem BioAssay data set.
6 Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2; 48(11):3808-15.

If you find any error in data or bug in web service, please kindly report it to Dr. Zhang and Dr. Mou.